Pharvaris (NASDAQ:PHVS - Get Free Report) shares were down 5.7% during mid-day trading on Wednesday . The stock traded as low as $14.98 and last traded at $14.57. Approximately 93,257 shares changed hands during mid-day trading, an increase of 100% from the average daily volume of 46,548 shares. The stock had previously closed at $15.45.
Analyst Ratings Changes
Separately, JMP Securities boosted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.
Read Our Latest Research Report on PHVS
Pharvaris Stock Performance
The company has a market capitalization of $784.87 million, a P/E ratio of -5.36 and a beta of -3.02. The business has a 50 day moving average of $17.40 and a 200-day moving average of $19.20.
Institutional Trading of Pharvaris
A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. Patient Square Capital LP bought a new stake in shares of Pharvaris during the 3rd quarter valued at $4,488,000. Soleus Capital Management L.P. grew its position in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after buying an additional 216,483 shares in the last quarter. FMR LLC grew its position in Pharvaris by 3.6% during the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after buying an additional 189,714 shares in the last quarter. Octagon Capital Advisors LP grew its position in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after buying an additional 157,530 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after buying an additional 118,408 shares in the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
